Key Finding: CGT Patient Access Requires Manufacturing & Logistics Strategy, Faces Public Communication Gaps
At Cell Summit 2026, discussions focused on strategies to improve patient access to cell and gene therapies (CGTs), emphasizing the need for more qualified hospitals, local readiness, and integrated digital workflows. An expert from CTI Clinical Trial & Consulting noted a paradigm shift from patients traveling to specialized centers to moving capabilities closer to patients. However, scaling clinical trial operations presents significant logistical hurdles in apheresis, cryostorage, product handling, and coordinating drug import/export. Furthermore, a communication gap between the biopharmaceutical industry and the public was highlighted, underscoring the importance of explaining complex therapies in simpler language to build trust.
Technical & Business Details: Scale-Up Challenges and the Importance of Closed Processes
The cell and gene therapy industry needs to increase commercial GMP capacity to meet growing demands and reduce the cost of goods per dose. Optimized bioprocesses facilitate scale-up from clinical to commercial levels, which can involve transitioning from 2D adherence-based to 3D suspension-based cell culture in bioreactors. Implementing closed, automated process environments is essential for improving scalability and patient accessibility, especially for autologous therapies. This ensures product consistency and safety while reducing manual handling and contamination risks.
Challenges in scaling clinical trials are multifaceted. They include efficient management of apheresis (the procedure to separate specific cellular components from blood), optimizing cryostorage techniques to maintain long-term quality of cells and products, and careful handling and transport of delicate biological products. These logistical complexities are further compounded by varying national regulatory frameworks and customs procedures, particularly in international clinical trials. Strengthening supply chain resilience and providing high-quality, regionally aligned supply options are crucial to supporting long-term commercial strategies.
Background & Industry Context: Building Trust and Fostering Social Acceptance
Public misunderstanding of biologics, monoclonal antibodies, and especially gene-modified viruses for therapeutic administration is pervasive and contributes to distrust in the industry. Attendees at Cell Summit 2026 recognized the need to bridge this communication gap by explaining scientific complexities in simpler, more accessible language. For instance, educating the public on “how biology shapes lives and the critical work of drug developers and manufacturers” is key. This approach can enhance social acceptance of emerging CGTs and facilitate broader adoption of these therapies.
Strategic Significance & Outlook: Widespread CGT Adoption and a Sustainable Ecosystem
For CGTs to reach a broad patient population, continuous innovation in manufacturing, logistics, and communication strategies is imperative. The adoption of decentralized manufacturing models and advanced digital supply chain management will reduce geographical barriers to therapeutic access. Concurrently, proactive and transparent communication with the public will deepen trust and understanding of emerging medical technologies, forming the foundation for a sustainable CGT ecosystem. Through these efforts, cell and gene therapies can fully realize their potential to save more lives and improve quality of life.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments